Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
201-220 of 3,900 trials

Marginal Zone Lymphoma: Mosunetuzumab-Lenalidomide Study

We are investigating whether the combination of Mosunetuzumab and Lenalidomide is more effective than standard treatments for patients with relapsed or refractory Marginal Zone Lymphoma. The study aims to assess how well this new treatment works and its safety.

Marginal Zone Lymphoma>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesHematologyOncology

Myeloma: [68Ga]Ga-PentixaFor PET Imaging Study

We are studying a new imaging method to see how accurately it detects myeloma at the beginning of treatment. This may help improve risk assessment and disease management for patients.

Multiple Myeloma>2 yearsSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesCost ReimbursementInternal MedicineOncology

Small-Cell Lung Cancer: BI 764532 Study

We are testing how well the drug BI 764532 is taken up by tumors in patients with small-cell lung cancer or neuroendocrine cancer. This study aims to understand its potential effectiveness in treating these cancers.

Advanced CancerLarge Cell Neuroendocrine Lung Carcinoma (LCNEC)Neuroendocrine Carcinoma (NEC)>2 yearsSafety phase (I)Oncology

Glioblastoma: L19TNF and Lomustine Study

We are evaluating a new treatment combining L19TNF with lomustine for patients with glioblastoma at their first progression. This study aims to understand how safe and effective this combination is.

Glioblastoma>2 yearsSafety phase (I)Efficacy phase (II)Oncology

Pancreatic Cancer: KISIMA-02 Vaccine Therapy

We are testing a new vaccine-based immunotherapy for patients with pancreatic cancer. This study aims to see if it can enhance the effectiveness of current treatments.

Pancreatic Cancer>2 yearsSafety phase (I)Oncology

Psilocybin for Hospitalized Patients with Treatment-Resistant Depression

We are studying the safety and feasibility of psilocybin-assisted psychotherapy for patients with treatment-resistant depression in a hospital setting. This research aims to explore its effects on depression and the overall experience of patients.

Treatment-Resistant DepressionEfficacy phase (II)>20 visitsNo PlaceboInvestigational MedicinesPartially RemotePsychiatry

Remifentanil for Intubation in Newborns

We are studying the best dose of remifentanil to safely sedate newborns during intubation. Our goal is to ensure effective sedation with minimal side effects.

Stable Neonates Requiring Intubation>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesInternal MedicineOtolaryngologyPediatrics

Leukemia and Lymphoma: Dasatinib and Venetoclax Study for Children

We are testing two new drugs for children with relapsed or refractory leukemia or lymphoma that have specific genetic mutations. The goal is to assess safety and see if these drugs can effectively treat their condition.

Lymphoblastic Lymphoma and Acute Lymphoblastic Leukemia1-2 yearsSafety phase (I)Efficacy phase (II)No PlaceboStandard MedicinesCost ReimbursementHematologyOncology

Leukemia and Lymphoma: Ruxolitinib and Venetoclax Study

We are studying the safety and effectiveness of ruxolitinib and venetoclax in children with relapsed or refractory leukemia or lymphoma that have specific genetic mutations. This research aims to find better treatment options for these young patients.

Lymphoblastic Lymphoma and Acute Lymphoblastic Leukemia>2 yearsSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementHematologyOncology

Hematological Cancers in Children: New Drug Combination Study

We are testing a combination of Trametinib, Dexamethasone, Cyclophosphamide, and Cytarabine for children with relapsed or refractory hematological malignancies. The goal is to assess safety and see if it works for patients with specific genetic changes.

Acute Lymphoblastic Leukemia and Lymphoblastic LymphomaSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesOncologyPediatrics

Takotsubo Syndrome: New Treatment Approaches

We are studying whether a combination of adenosine and dipyridamole improves outcomes for patients with Takotsubo Syndrome. Additionally, we’re testing if apixaban can lower the risk of blood clots in these patients.

Takotsubo Syndrome>2 yearsMonitoring phase (IV)Standard MedicinesPartially RemoteCardiologyInternal Medicine

Chronic Lymphocytic Leukemia: Mosunetuzumab and Venetoclax Study

We are testing a new treatment combining Mosunetuzumab and Venetoclax for patients with relapsed or refractory chronic lymphocytic leukemia. The goal is to evaluate its safety and effectiveness compared to Mosunetuzumab alone.

Chronic Lymphocytic Leukemia>2 yearsSafety phase (I)Oncology

Generalized Myasthenia Gravis: Ravulizumab for Kids

We are studying the effects of Ravulizumab in children with Generalized Myasthenia Gravis to see how well it works and its safety. This trial will help us understand if it improves their quality of life.

Generalized Myasthenia Gravis3-6 monthsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboStandard MedicinesPartially RemoteNeurologyPediatrics

Acute Ischemic Stroke: Redasemtide Study

We are investigating whether redasemtide can improve recovery in adults who have had an acute ischemic stroke. Participants will receive either the medication or a placebo to compare effects.

Ischaemic Stroke>2 yearsEfficacy phase (II)≤5 visitsInvestigational MedicinesCost ReimbursementPartially RemoteCardiologyNeurology

Prostate Cancer Imaging: PSMA-PET vs. mpMRI

We are comparing two imaging methods to see which better identifies critical areas in high-risk prostate cancer. This study may help improve diagnosis and treatment planning for patients.

Prostate Cancer>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesOncologyUrology

Rituximab for Heart Attack Recovery

We are studying whether a single injection of rituximab can improve heart function in patients who have had a heart attack. This trial compares its effects to a placebo to see if it helps reduce heart damage.

ST Segment Elevation Myocardial InfarctionAcute Myocardial Infarction>2 yearsEfficacy phase (II)≤5 visitsStandard MedicinesPartially RemoteCardiologyInternal Medicine

Prostate Cancer: Apalutamide with Radiation Therapy

We are studying whether adding stereotactic body radiation therapy to Apalutamide improves treatment outcomes for men with low burden metastatic hormone-sensitive prostate cancer. This trial compares standard treatment alone to the combination therapy.

Prostate Cancer>2 yearsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesOncologyUrology

Polymyalgia Rheumatica: Secukinumab Injection Study

We are studying whether secukinumab, combined with a glucocorticoid taper, can help patients with polymyalgia rheumatica achieve better remission compared to a placebo. This trial also looks at the safety and quality of life for participants.

Polymyalgia Rheumatica1-2 yearsConfirmation phase (III)16-20 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteInternal MedicineRheumatology

Asthma in Children: QMF149 vs. Budesonide

We are studying whether QMF149 can improve lung function and reduce asthma symptoms in children aged 6 to under 12 compared to Budesonide. This trial will help us understand which treatment works better for young patients.

Asthma6-12 monthsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPediatricsPulmonology

Ovarian Cancer: REGN5668 with Cemiplimab or REGN4018

We are studying the safety and effectiveness of REGN5668 when given with either Cemiplimab or REGN4018 for patients with ovarian cancer. This trial aims to find the best dose and see how well these combinations work.

Fallopian Tube CancerPrimary Peritoneal CancerOvarian CancerSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteGynecology and ObstetricsOncology